Alpine Group USVI’s Genetic Technologies Ltd. GENE Stock Holding History

Alpine Group USVI’s Portfolio GENE Stock Details GENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,422	Closed	-$17K	–	16
2019 Q2	$17K	Hold	1,422	–	–	0.05%	15
2019 Q1	$25K	Buy	+1,422	New	+$23.6K	0.07%	15
2017 Q2	$38K	Buy	+2,111	New	+$44.2K	0.01%	124

Other funds holding GENE

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

RCAG

Rehmann Capital Advisory Group Lansing, Michigan $1.92B AUM 16.97% 1-Year Est. Return

RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

Alpine Group USVI's GENE Position: Q3 2019 in Review

Alpine Group USVI sold out of Genetic Technologies Ltd. (GENE) in Q3 2019, closing a stake of 1,422 shares — an estimated $17K sold.

Alpine Group USVI first reported a position in GENE in Q2 2017 and held it in 3 quarters. The position peaked at $38K in Q2 2017. 6 funds tracked by Wall St. Rank hold GENE as of Q3 2019.

Alpine Group USVI reported no remaining Genetic Technologies Ltd. position as of Q3 2019 after selling out during the quarter.
Alpine Group USVI sold 1,422 Genetic Technologies Ltd. shares in Q3 2019, an estimated $17K.
Alpine Group USVI first reported a position in Genetic Technologies Ltd. in Q2 2017 and held it in 3 quarters.
Alpine Group USVI's Genetic Technologies Ltd. position peaked at $38K in Q2 2017.
6 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q3 2019.

Based on Alpine Group USVI's 13F filing for Q3 2019, filed 11 Oct 2019.